□□□

□□

□□

□□(Burbach, 2011)□

□□□□□

□□□□□□□□□□□□(Kastin, 2000, Russo, 2017)□□□□□□□□□□□□□□□□□□□□□□□□□□□□□1□□□□□□□□□N□□-□□□□□□□□□□□□□□□□□□□□□□□(Burbach, 2011)□□N□□□□□□□□□□□□□□□□(Hook, 2008, Sun and Zhao, 2017, Mains and Eipper, 1999)□□□□□□□□□C□□□(Eipper, 1992)□□□□□□□□□□□□□□□α□□□□□□1□(Mains and Eipper, 1999)□



□1□□□

⊠⊠(Mains and Eipper, 1999, Russo, 2017)⊠⊠2⊠⊠



⊠ 2⊠⊠⊠
⊠⊠⊠⊠⊠⊠⊠⊠⊠Ca2+⊠⊠⊠⊠⊠⊠⊠⊠⊠

⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠

⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠ (Hökfelt et al., 2003, van den Pol, 2012)⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠(Russo, 2017)⊠⊠⊠ (Russo, 2017)⊠⊠(Mains and Eipper, 1999)⊠

⊠⊠2⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠ (van den Pol, 2012, Russo, 2017)⊠

⊠⊠⊠ ⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠(Russo, 2017)⊠

⊠⊠(Russo, 2017)⊠

⊠⊠⊠⊠

⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠G⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠(Hökfelt et al., 2003, Russo, 2017)⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠ (Hökfelt et al., 2003)⊠
⊠⊠⊠(Russo, 2017)⊠

⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠

⊠⊠⊠(Albrechtsen and Rehfeld, 2021)⊠

□□□□□□□□□□□□□□□□□□□□□□□□□CGRPs□□mRNAs□□□□□(Amara et al., 1982)□

□□3A□(Rehfeld et al., 2008)□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□proCCK□□□□□□□CCK-33□CCK-12□CCK-8□□□□□□□□□□□□□□□□□□-28□□□□□□□□-14□□□□□(Albrechtsen and Rehfeld, 2021)□



□ 3□□□□□□□□□□
A□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□
B□□□□□□□□□□□□□□□□□□□□□□□□□□□□□

□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□3B□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□(Albrechtsen and Rehfeld, 2021)□

□□□□

□□□(Russo, 2017)□

□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□9□□□□□□4A□4B□□□□□IHC□□□□□□□□7□□□(Mains and Eipper, 1999)□





[illegible]4A[illegible] [illegible]-[illegible](cat. no. 403 004, [illegible] 1:500, [illegible])[illegible]PFA[illegible]DAPI[illegible]

[illegible] 4B[illegible] [illegible]-[illegible] (cat. no. 408 004, [illegible] 1:500, [illegible])[illegible]PFA[illegible]DAPI[illegible]

[illegible](Hökfelt et al., 2003)[illegible]CGRP[illegible]5A[illegible]5B[illegible](Edvinsson et al., 2018, Russo, 2015)[illegible]





☒5A☒☒☒☒☒☒-☒☒☒☒☒ (cat. no. 459 005, ☒☒☒☒ 1:500,☒☒)☒☒☒PFA☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒DAPI☒☒☒☒☒☒☒☒

☒ 5B☒☒☒☒☒☒-☒☒☒☒☒☒☒☒☒☒☒(cat. no. 414 004, ☒☒☒☒ 1:1000, DAB)☒☒☒PFA☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒

☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒Y☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒☒6A☒6B☒☒☒☒☒IHC☒☒(Hökfelt et al., 2003)☒





⊠6A⊠⊠⊠⊠⊠-⊠⊠⊠ Y ⊠⊠ (cat. no. 394 006, ⊠⊠⊠⊠ 1:500, ⊠⊠)⊠⊠⊠PFA⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠DAPI⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠(10mM Tris, 1mM EDTA, pH 9.0, ⊠ 60°C⊠⊠⊠) ⊠

⊠6B⊠⊠⊠⊠⊠⊠-⊠⊠⊠⊠⊠⊠ (cat. no. 446 004, ⊠⊠⊠⊠ 1 : 1000, DAB)⊠⊠⊠PFA⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠

⊠⊠

⊠⊠⊠	⊠⊠
ACTH	⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠(Gallo-Payet, 2016)⊠
AGRP	⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠(Ilnytska and Argyropoulos, 2008)⊠
CART	⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠(Rogge et al., 2008)⊠
CCK-8	⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠(Lee and Soltesz, 2011)⊠
CGRP	⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠(Benarroch, 2011)⊠
CRF	⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠(Vitoratos et al., 2006)⊠
Galanin	⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠/⊠⊠⊠⊠⊠(Lang et al., 2015)⊠
Neuropeptide S	⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠(Grund and Neumann, 2019)⊠
Neuropeptide Y	⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠(Reichmann and Holzer, 2016)⊠
Neurotensin	⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠(Saiyasit et al., 2018)⊠

Orexin	⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠(Nixon et al., 2015)⊠
Oxytocin	⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠(Lee et al., 2009)⊠
Somatostatin	⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠(Gehete et al., 2010)⊠
Substance P	⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠(Schank and Heilig, 2017)⊠
Vasopressin	⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠(Caldwell et al., 2008)⊠
VIP	⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠(Iwasaki et al., 2019).

⊠⊠⊠⊠⊠⊠⊠

⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠

⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠7A⊠7B⊠IHC⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠(Hökfelt et al., 2003)⊠





⊠7A⊠⊠⊠⊠⊠⊠-⊠⊠⊠A⊠⊠(cat. no. 389 004, ⊠⊠⊠⊠1:500, ⊠⊠)⊠⊠⊠PFA⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠DAPI⊠⊠⊠⊠⊠⊠⊠

⊠7B⊠⊠⊠⊠⊠⊠-⊠⊠⊠A/B⊠⊠(cat. no. 389 104, ⊠⊠⊠⊠1:500, ⊠⊠)⊠⊠⊠PFA⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠DAPI⊠⊠⊠⊠⊠⊠⊠

⊠⊠⊠⊠⊠⊠⊠70⊠⊠(Hökfelt et al., 2003)⊠
⊠⊠⊠(Sevivas and Fresco, 2022, Vandervorst et al., 2021)⊠

[illegible]

[illegible]IHC[illegible]IHC-P[illegible]8A[illegible]8B[illegible]ICC[illegible]





[illegible]8A[illegible][illegible]-[illegible](cat. no. 452 005, [illegible] 1:500, [illegible])[illegible]-[illegible]Y[illegible](cat. no. 394 006, [illegible]1:500, [illegible])[illegible]PFA[illegible]DAPI[illegible]

[illegible]8B[illegible][illegible]-[illegible]-28[illegible](cat. no. 366 004, [illegible]1:500, DAB)[illegible]PFA[illegible]DAPI[illegible]





[illegible]**8C**[illegible]-8[illegible](cat. no. 438 004,[illegible]1:500,[illegible]) [illegible]-MAP 2[illegible](cat. no. 188 002, [illegible]1:1000, [illegible])[illegible]PFA[illegible]DAPI[illegible]

[illegible]**8D**[illegible]-[illegible](cat. no. 443 005, [illegible]1:100, [illegible])[illegible]-MAP 2 [illegible](cat. no. 188 002, [illegible]1:1000, [illegible])[illegible]PFA[illegible]DAPI[illegible]

[illegible]

Cat. No.	Product Description	Application	Quantity	Price	Cart
452 005	ACTH, Guinea pig, affinity	IHC IHC-P (FFPE)	50 µg	US$465.00	
438 004	CCK-8, Guinea pig, antiserum	ICC IHC IHC-P (FFPE)	100 µl	US$375.00	
414 004	CGRP, Guinea pig, antiserum	ICC IHC IHC-P (FFPE) iDISCO Clarity	100 µl	US$370.00	
414 017	CGRP, rat, IgG K.O.	IHC IHC-P (FFPE)	100 µg	US$420.00	
259 002	Chromogranin A, rabbit, antiserum	WB	200 µl	US$360.00	
259 003	Chromogranin A, rabbit, affinity K.O.	WB ICC IHC IHC-P (FFPE)	50 µg	US$460.00	
259-0P	Chromogranin A, control protein		100 µg	US$110.00	
259 103	Chromogranin B, rabbit, affinity K.O.	WB ICC IHC IHC-P (FFPE) EM	50 µg	US$380.00	

259-1P	Chromogranin B, control protein		100 µg	US$110.00
529 004	CRF, Guinea pig, antiserum	ICC IHC	100 µl	US$370.00
446 004	Galanin, Guinea pig, antiserum	ICC IHC IHC-P (FFPE)	100 µl	US$370.00
468 003	Ghrelin, rabbit, affinity	IHC IHC-P (FFPE)	50 µg	US$380.00
514 003	GIP, rabbit, affinity	IHC IHC-P (FFPE)	50 µg	US$380.00
471 005	GLP-1, Guinea pig, affinity	Dot blot IHC IHC-P (FFPE)	50 µg	US$465.00
471 203	GLP-2, rabbit, affinity	Dot blot IHC IHC-P (FFPE)	50 µg	US$380.00

Result count: **30**

⊠⊠⊠Beate Friedrich⊠⊠

Beate⊠⊠⊠
⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠⊠

⊠⊠⊠⊠

Albrechtsen and Rehfeld, 2021: On premises and principles for measurement of gastrointestinal peptide hormones. PMID: 33811948

Amara et al., 1982: Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. PMID: 6283379

Benarroch, 2011: CGRP: sensory neuropeptide with multiple neurologic implications. PMID: 21768598

Burbach, 2011: What are neuropeptides? PMID: 21922398

Caldwell et al., 2008: Vasopressin: behavioral roles of an “original” neuropeptide. PMID: 18053631

Edvinsson et al., 2018: CGRP as the target of new migraine therapies – successful translation from bench to clinic. PMID: 29691490

Eipper, 1992: The biosynthesis of neuropeptides: peptide alpha-amidation. PMID: 1575450

Gahete et al., 2010: Somatostatin and its receptors from fish to mammals. PMID: 20633132

Gallo-Payet, 2016: 60 years of POMC: adrenal and extra-adrenal functions of ACTH. PMID: 26793988

Grund and Neumann, 2019: Brain neuropeptide S: via GPCR activation to a powerful neuromodulator of socio-emotional behaviors. PMID: 30112573

Hökfelt et al., 2003: Neuropeptides: opportunities for drug discovery. PMID: 12878434

Hook, 2008: Proteases for processing proneuropeptides into peptide neurotransmitters and hormones. PMID: 18184105

Ilnytska and Argyropoulos, 2008: The role of the Agouti-related protein in energy balance regulation. PMID: 18470724

Iwasaki et al., 2019: Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system. PMID: 31559013

Kastin, 2000: What is a neuropeptide? PMID: 10675912

Lang et al., 2015: Physiology, signaling, and pharmacology of galanin peptides and receptors: three decades of emerging diversity. PMID: 25428932

Lee and Soltesz, 2011: Cholecystokinin: a multi-functional molecular switch of neuronal circuits. PMID: 21154912

Lee et al., 2009: Oxytocin: the great facilitor of life. PMID: 19482229

Mains and Eipper, 1999: The Neuropeptides. Bookshelf ID: NBK28247 https://www.ncbi.nlm.nih.gov/books/NBK28247

Nixon et al., 2015: Sleep disorders, obesity, and aging: the role of orexin. PMID: 25462194

Rehfeld et al., 2008: The cell-specific pattern of cholecystokinin peptides in endocrine cells versus neurons is governed by the expression of prohormone convertases 1/3, 2, and 5/6. PMID: 18096669

Reichmann and Holzer, 2016: Neuropeptide Y: A stressful review. PMID: 26441327

Rogge et al., 2008: CART peptides : regulators of body weight, reward and other functions. PMID: 18802445

Russo, 2015: Calcitonin gene-related peptide (CGRP): A new target for migraine. PMID: 25340934

Russo, 2017: Overview of neuropeptides: Awakening the senses? PMID: 28485842

Saiyasit et al, 2018: Potential roles of neurotensin on cognition in conditions of obese-insulin resistance. PMID: 30279001

Schank and Heilig, 2017: Substance P and the Neurokinin-1 Receptor: The new CRF. PMID: 29056150

Sevivas and Fresco, 2022: Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review. PMID: 35659086

Sun and Zhao, 2017: Peptide hormones as tumor markers in clinical practice. PMID: 29054271

Van den Pol, 2012: Neuropeptide transmission in brain circuits. PMID: 23040809

Vandervorst et al., 2021: CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs. PMID: 34696711

Vitoratos et al., 2006: “Reproductive” corticotropin-releasing hormone. PMID: 17308156